Gilead Q4 GAAP EPS $0.30, revenue $7.2B (-2% YoY); 2022 guidance $23.8-24.3B

GILEAD SCIENCES, INC.

2021-FY EPS reported $4.93 revenue$27,305,000,000

GAAP diluted EPS $0.30 vs $1.23 YoY; non-GAAP $0.69 vs $2.19 (includes $1.25B legal charge)
Q4 product sales $7.2B (-2% YoY); ex-Veklury up 8% to $5.8B
Biktarvy sales up 22% YoY to $4.5B; Cell Therapy up 47% to $239M
2022 guidance: product sales $23.8-24.3B; GAAP EPS $4.70-5.20; non-GAAP EPS $6.20-6.70
Cash flow: $3.2B operating; debt repayment $1B; dividends $894M; cash $7.8B at Dec 31

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.